You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Combodart Efficacy

Combodart is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).

Dutasteride-tamsulosin is a combination of two drugs: dutasteride, a dual 5 α-reductase inhibitor (5 ARI) and tamsulosin hydrochloride, an antagonist of α1a and α1d adrenoreceptors. These drugs have complementary mechanisms of action that rapidly improve symptoms, urinary flow and reduce the risk of acute urinary retention (AUR) and the need for BPH related surgery.

The table belows explains how the two medicines combined in Combodart, dutasteride (5ARI) and
tamsulosin hydrochloride (α-blocker), work together.

Please refer to clinical data page for further information on Combodart studies.


  1. Combodart Prescribing information available at, last accessed May 2018
  2. Oelke M et al. Guidelines on management of male lower urinary tract symptoms (LUTS), including Benign Prostatic Obstruction (BPO). European Association of Urology, 2012.
  3. Madersbacher S et. al EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPHGuidelines). Euopean Urology, 2004, 46: 547-554

Combodart is registered trademark of the GlaxoSmithKline Group of companies